2000
Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months
Schoen R, Sikand V, Caldwell M, Van Hoecke C, Gillet M, Buscarino C, Parenti D. Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clinical Therapeutics 2000, 22: 315-325. PMID: 10963286, DOI: 10.1016/s0149-2918(00)80035-1.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineThird doseRecombinant outer surface protein A (OspA) vaccineOuter surface protein A (OspA) vaccineRecombinant outer surface proteinGeometric mean antibody titersVaccine 1 monthMost adverse eventsDoses of vaccineMean antibody titersLyme disease endemic areaEnzyme-linked immunosorbentDisease-endemic areasA vaccineAdverse eventsRandomized studyVaccination scheduleImmunogenicity profileSafety profileAntibody titersMonths 0Month 2Clinical trialsEfficacy trials
1996
Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine
Ma J, Hine P, Clough E, Fish D, Coughlin R, Beltz G, Shew M. Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine. Vaccine 1996, 14: 1366-1374. PMID: 9004447, DOI: 10.1016/s0264-410x(96)00045-x.Peer-Reviewed Original ResearchConceptsCanine Lyme disease vaccineLyme disease vaccineDisease vaccineGeometric mean antibody titersInjection site swellingMean antibody titersTypical clinical signsMonths postchallengeVaccination timeSecond vaccinationBorrelial antigensSpirochetal antigensAntibody titersProtective efficacyControl beaglesAdverse reactionsVaccinated dogsClinical signsImmunological memoryLocal reactionsAntibody productionNormal beaglesVaccinatesLyme diseaseOsp A
1995
REACTIVITY OF WHITE-FOOTED MOUSE AND RACCOON SERA TO WHOLE CELL AND RECOMBINANT ANTIGENS OF BORRELIA BURGDORFERI
Magnarelli L, Anderson J, Flavell R, Fikrig E. REACTIVITY OF WHITE-FOOTED MOUSE AND RACCOON SERA TO WHOLE CELL AND RECOMBINANT ANTIGENS OF BORRELIA BURGDORFERI. Journal Of Wildlife Diseases 1995, 31: 339-44. PMID: 8592354, DOI: 10.7589/0090-3558-31.3.339.Peer-Reviewed Original ResearchConceptsWhole cell antigenCell antigensRecombinant antigensSpecific recombinant antigensGeometric mean antibody titersMean antibody titersPresence of antibodiesB. burgdorferi infectionEnzyme-linked immunosorbentWhite-footed miceAntibody titersBorrelia burgdorferi sensu strictoBurgdorferi infectionBurgdorferi sensu stricto
1991
Antibody Responses to Haemophilus influenzae Type b Vaccines in Men with Human Immunodeficiency Virus Infection
Steinhoff M, Auerbach B, Nelson K, Vlahov D, Becker R, Graham N, Schwartz D, Lucas A, Chaisson R. Antibody Responses to Haemophilus influenzae Type b Vaccines in Men with Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1991, 325: 1837-1842. PMID: 1683682, DOI: 10.1056/nejm199112263252603.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionInfluenzae type b vaccineAsymptomatic HIV infectionImmunodeficiency virus infectionSymptomatic HIV infectionType b vaccineHIV infectionAntibody responsePRP vaccineB vaccineVirus infectionH. influenzae type b vaccineHaemophilus influenzae type b vaccineType b polysaccharide vaccineGeometric mean antibody titersHIV-seropositive menPRP antibody titersPutative protective levelGreater antibody responseH. influenzae type b.Mean antibody titersSeronegative subjectsCD4 lymphocytesPolysaccharide vaccineSeronegative men
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply